Modulation of retinoblastoma cell characteristics by hexamethylene bis-acetamide and other differentiating agents in culture.
The undifferentiated Y-79 retinoblastoma cell line can be induced by specific agents to express characteristics of mature retinal cells. In the present study, attached Y-79 cell cultures were treated with hexamethylene bis-acetamide (HMBA) and other differentiating agents and examined for "neuronal" and other properties. Immunocytochemical staining was performed with antibodies against neuron- and retina-specific antigens, [synaptophysin, interphotoreceptor retinoid-binding protein (IRBP), neural cell adhesion molecule (N-CAM), and rod- and cone-specific transducin (TR alpha and TC alpha)] and microtubule-associated protein (MAP-1) and tubulin. Enhanced expression of tubulin was observed with cAMP treatment in FBS media. Expression of N-CAM was observed in all groups. Morphological differentiation was pronounced with HMBA and butyrate treatment, with HMBA inducing increased tubulin expression after 2 weeks of treatment. Expression of TR alpha was minimal under all culture conditions, whereas TC alpha was ubiquitously expressed. This supports the concept that Y-79 retinoblastoma is predominantly of cone neuronal origin and that, surprisingly, immunocytochemical differentiation is not correlated with the marked morphological changes induced by the major differentiating agents used.
Rajagopalan
S
S
Department of Ophthalmology, University of Maryland, Baltimore 21201.
Rodrigues
M
M
Polk
T
T
Wilson
D
D
Chader
G J
GJ
Hayden
B J
BJ
D000081:Acetamides / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D015816:Cell Adhesion Molecules, Neuronal / Q000032:analysis; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D000242:Cyclic AMP / Q000494:pharmacology*; D005134:Eye Neoplasms / Q000737:chemistry / Q000473:pathology*; D005136:Eye Proteins; D006801:Humans; D007150:Immunohistochemistry; D008869:Microtubule-Associated Proteins / Q000032:analysis; D012044:Regression Analysis; D012175:Retinoblastoma / Q000737:chemistry / Q000473:pathology*; D012177:Retinol-Binding Proteins / Q000032:analysis; D016708:Synaptophysin / Q000032:analysis; D015293:Transducin / Q000032:analysis; D014212:Tretinoin / Q000494:pharmacology*; D014404:Tubulin / Q000032:analysis; D014407:Tumor Cells, Cultured; D000099214:Retinol-Binding Proteins, Interstitial
D000081:Acetamides; D000970:Antineoplastic Agents; D002087:Butyrates; D015816:Cell Adhesion Molecules, Neuronal; D000242:Cyclic AMP; D005136:Eye Proteins; D008869:Microtubule-Associated Proteins; D012177:Retinol-Binding Proteins; D016708:Synaptophysin; D015293:Transducin; D014212:Tretinoin; D014404:Tubulin; D000099214:Retinol-Binding Proteins, Interstitial; C014026:hexamethylene bisacetamide